Global Gastrointestinal Drug Market Overview and Forecast to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape
Disease and disorders involving the gastrointestinal system are among the most common conditions encountered worldwide, and many of them can have a significant impact on quality of life. The direct and indirect socio-economic burden associated with gastrointestinal disorders is profound. The direct costs of medical consultations and treatments in the US for gastroesophageal reflux disease alone are estimated to amount to $9.3 billion, while the indirect costs due to absenteeism and impairment in work performance total $75 billion (Chait, 2010).
View full press release